Literature DB >> 32463153

Patient-Reported Outcomes in Oncology Clinical Trials: Stakeholder Perspectives from the Accelerating Anticancer Agent Development and Validation Workshop 2019.

Vishal Bhatnagar1, Stacie Hudgens2, Elisabeth Piault-Louis3, Lee Jones4, Julia A Beaver5, H Kim Lyerly6, Gregory Reaman1, Thomas Fleming7, Paul G Kluetz1.   

Abstract

Entities:  

Keywords:  Clinical trials; Patient-reported outcome measures

Mesh：

Substances：

Year:  2020        PMID： 32463153      PMCID： PMC7543246          DOI： 10.1634/theoncologist.2020-0062

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159            Impact factor:   5.837


× No keyword cloud information.
  5 in total

1.  Toward patient-centered drug development in oncology.

Authors:  Ethan Basch
Journal:  N Engl J Med       Date:  2013-07-03       Impact factor: 91.245

Review 2.  Fit for purpose and modern validity theory in clinical outcomes assessment.

Authors:  Michael C Edwards; Ashley Slagle; Jonathan D Rubright; R J Wirth
Journal:  Qual Life Res       Date:  2017-07-07       Impact factor: 4.147

Review 3.  Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review: Perspectives From Industry, the Food and Drug Administration, and the Patient.

Authors:  Ethan Basch; Cindy Geoghegan; Stephen Joel Coons; Ari Gnanasakthy; Ashley F Slagle; Elektra J Papadopoulos; Paul G Kluetz
Journal:  JAMA Oncol       Date:  2015-06       Impact factor: 31.777

4.  Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms.

Authors:  Paul G Kluetz; Ashley Slagle; Elektra J Papadopoulos; Laura Lee Johnson; Martha Donoghue; Virginia E Kwitkowski; Wen-Hung Chen; Rajeshwari Sridhara; Ann T Farrell; Patricia Keegan; Geoffrey Kim; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2016-01-12       Impact factor: 12.531

5.  Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer.

Authors:  K M Islam; T Anggondowati; P E Deviany; J E Ryan; A Fetrick; D Bagenda; M S Copur; A Tolentino; I Vaziri; H A McKean; S Dunder; J E Gray; C Huang; A K Ganti
Journal:  BMC Cancer       Date:  2019-08-27       Impact factor: 4.430
  5 in total
  1 in total

1.  E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.

Authors:  Roisin M Connolly; Fengmin Zhao; Kathy D Miller; Min-Jung Lee; Richard L Piekarz; Karen L Smith; Ursa A Brown-Glaberman; Jennifer S Winn; Bryan A Faller; Adedayo A Onitilo; Mark E Burkard; George T Budd; Ellis G Levine; Melanie E Royce; Peter A Kaufman; Alexandra Thomas; Jane B Trepel; Antonio C Wolff; Joseph A Sparano
Journal:  J Clin Oncol       Date:  2021-08-06       Impact factor: 50.717
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.